Chris Boshoff/LinkedIn
Feb 5, 2025, 00:06
Chris Boshoff: Pfizer’s BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Phase 3 BREAKWATER Trial
Chris Boshoff, Chief Oncology Officer and President of Research and Development at Pfizer, shared on LinkedIn:
“I’m extremely pleased to share we have announced positive topline progression-free survival (PFS) and overall survival (OS) results from the Phase 3 study of our targeted treatment regimen in patients with BRAF V600E-mutant metastatic Colorectal Cancer (mCRC).
These results support the potential for this treatment regimen to be practice-changing for this patient population, which has historically had limited treatment options and poor outcomes.
We look forward to discussing these data with global health authorities to bring this treatment to more patients around the world, as soon as possible.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 15:59
Sep 9, 2025, 15:49
Sep 9, 2025, 15:46
Sep 9, 2025, 15:42
Sep 9, 2025, 15:28